Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

Summary

A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.

Timeline

Start

2018-05-03

Primary completion

2021-08-17

Completion

2021-09-08

Outcome

Met primary endpoint

registry analysis (superiority test); Abaloparatide vs Placebo; p <0.0001; Least Squares (LSM) Means Difference 7.3165 (99% CI 5.0668 to 9.5663); NCT03512262 ↗

Publications

• Background Rizzoli R, Bonjour JP, Ferrari SL. Osteoporosis, genetics and hormones. J Mol Endocrinol. 2001 Apr;26(2):79-94. doi: 10.1677/jme.0.0260079.
• Background Mannstadt M, Juppner H, Gardella TJ. Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol. 1999 Nov;277(5):F665-75. doi: 10.1152/ajprenal.1999.277.5.F665.
• Background Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993 Dec;14(6):690-709. doi: 10.1210/edrv-14-6-690. No abstract available.
• Deal C, Bostrom MP, Sheth NP, Humbert L, Krohn KD, Wang Y, Boxberger JI. The effects of abaloparatide on acetabular bone mineral density and proximal femur strength in men with osteoporosis. J Clin Densitom. 2026 Apr-Jun;29(2):101686. doi: 10.1016/j.jocd.2026.101686. Epub 2026 Feb 17.

Drugs

Indications